Lumakras (Sotorasib) Patent Expiration, LOE Window & CMS Spending

Lumakras (Sotorasib) by Amgen: FDA Orange Book core substance LOE 2040-05-20 (last listed 2040-09-15), 0 AB generics, $171.9M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAmgen
FDA Application & PathwayN214665 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2040-05-20
Last Listed Patent or Exclusivity Date2040-09-15
Orange Book Patents (*PED Extensions)6 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$171.9M
2024 Medicare Part D Spend$153.6M
2024 Medicaid Spend$18.3M
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 18.0% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Amgen across sibling Meru public-data platforms.